Loading company
ALX Oncology Holdings Inc.
ALXO · Nasdaq · ·
Next earnings: November 6, 2026
$1.34-4.3%Sep 29 close
- 1M
- -32.3%
- 6M
- -32.3%
- 1Y
- -26.0%
- 5Y
- -98.3%
ALXO · Nasdaq · ·
Next earnings: November 6, 2026
$1.34-4.3%Sep 29 close
ALX Oncology Holdings Inc. is scheduled to report next on November 6, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending December 31, 2020, against the same quarter a year earlier.
| Measure | 3 months toDec 31, 2020 | 3 months toDec 31, 2019 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $1.2M | -100.00% |
| Profit | -$18M | -$25.9M | +30.74% |
| Profit per share | -$0.13 | -$0.49 | +73.47% |
| Free Cash Flow | -$16.1M | -$23.5M | +31.46% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“We continue to execute against our strategy with discipline and focus, advancing both of our clinical programs toward meaningful value-creating milestones,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
ALX Oncology (Nasdaq: ALXO) is a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients’ lives. ALX Oncology’s lead therapeutic candidate, evorpacept, has demonstrated potential to serve as a cornerstone therapy upon which the future of immuno-oncology can be built. Evorpacept is currently being evaluated across multiple ongoing clinical trials in a wide range of cancer indications. ALX Oncology’s second pipeline candidate, ALX2004, is a novel EGFR-targeted antibody-drug conjugate with a differentiated mechanism of action. A Phase 1, dose-escalation trial of ALX2004 is ongoing in patients with EGFR-expressing solid tumors. More information is available at www.alxoncology.com and on LinkedIn and X .
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from ALX Oncology Holdings Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
ALX Oncology Holdings Inc. has no earnings call transcript available.